Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Ma Stacey reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director Stacey Ma received equity awards in the form of company stock. On May 21, 2026, she was granted 12,196 shares of common stock as deferred stock units and 4,678 shares as restricted stock units, both described as annual equity awards for non-employee directors. These are compensation-related grants at no cash purchase price, not open-market stock purchases or sales.
Elanco Animal Health director Art A. Garcia reported receiving stock-based compensation in the form of common stock units. On May 21, 2026, he acquired 12,196 deferred stock units as a pro-rated annual equity award for non-employee directors and 4,678 restricted stock units as an annual equity award. Both awards were granted at a stated price of $0.00 per share, reflecting compensation rather than open-market purchases. Each line in the filing shows updated direct holdings of Elanco common stock of 108,152 shares and 95,956 shares, respectively, following these grants.
Elanco Animal Health officer Rajeev A. Modi bought 4,911 shares of common stock in an open-market purchase at $20.35 per share, bringing his direct holdings to 160,812 shares. He also received a grant of 74.3671 deferred stock units, each tied to one share or its cash equivalent, which settle after employment ends or in a specified future year.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported an open-market purchase and a compensation-related award. A revocable trust associated with him bought 4,971 shares of common stock at $20.085 per share, bringing its indirect holdings to 171,971 shares. Separately, he received 142.3429 deferred stock units, each representing the right to one share of common stock or the cash equivalent, to be settled after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan. Following these updates, he directly holds 2,051,898 common shares and 24,306.4587 deferred stock units.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 9.9204 deferred stock units tied to company common stock. The award is a compensation-related acquisition at a reference price of $19.86 per unit, bringing his total deferred stock units to 84.4197. Each unit represents the right to receive one share of common stock or the cash equivalent, settling in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Incorporated disclosed that Dodge & Cox beneficially owns 68,944,100 shares of its common stock, equal to 13.9% of the class as of 03/31/2026.
The filing is an Amendment No. 5 to a Schedule 13G/A and notes that Dodge & Cox Stock Fund holds 45,270,700 shares (9.1%). The amendment was signed on 05/14/2026.
Elanco Animal Health Incorporated ownership disclosure: PRIMECAP MANAGEMENT CO/CA/ reports beneficial ownership of 45,840,956 shares of common stock, representing 9.22% of the class. The filing lists sole voting power of 45,573,360 shares and sole dispositive power of 45,840,956 shares.
Elanco Animal Health delivered solid top-line growth in the quarter ended March 31, 2026, with revenue rising 15% to $1,371 million, driven by double-digit gains in both pet health and farm animal products across U.S. and international markets.
Despite higher sales, net income declined to $57 million from $67 million, and diluted EPS fell to $0.11, as amortization, restructuring costs and higher interest expense, including on a liability for future royalty sales, weighed on profit. Cash flow from operations turned modestly positive, cash stood at $428 million, and long-term debt remained significant at about $3.9 billion. Elanco advanced its pipeline and strategy with approvals and launches for Zenrelia and Credelio Quattro and closed the AHV farm animal acquisition shortly after quarter end, while progressing its 2025 restructuring plan aimed at margin expansion.
Elanco Animal Health reported a strong first quarter of 2026 and raised its full-year outlook. Revenue was $1,371 million, up 15% year-over-year, with 10% organic constant currency growth. Adjusted EBITDA rose to $334 million, a 21% increase, and adjusted EBITDA margin improved to 24.5%. Reported EPS was $0.11, while adjusted EPS increased to $0.40, up 8% from 2025.
The company raised 2026 revenue guidance to $5,010–$5,085 million, implying 5%–7% organic constant currency growth, and lifted adjusted EBITDA guidance to $975–$1,005 million. Adjusted EPS guidance increased to $1.03–$1.09, with a 13% year-over-year increase at the midpoint. Elanco also improved its year-end net leverage ratio target to 3.0x–3.2x adjusted EBITDA from a current 3.5x.
Modi Rajeev A. reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc officer Rajeev A. Modi reported an award of 65.6122 deferred stock units on May 1, 2026, tied to Company common stock at a reference price of $22.51 per unit. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan. Following this grant, Modi directly holds a total of 9,265.6213 deferred stock units.